Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $76.00 Consensus Price Target from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned a consensus recommendation of “Hold” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $76.00.

A number of brokerages have issued reports on KYMR. Bank of America cut Kymera Therapeutics from a “buy” rating to a “neutral” rating and raised their target price for the stock from $65.00 to $80.00 in a report on Friday, September 10th. Morgan Stanley reduced their target price on Kymera Therapeutics from $69.00 to $68.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 18th. Finally, Zacks Investment Research lowered Kymera Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 11th.

Kymera Therapeutics stock traded up $0.68 during mid-day trading on Thursday, hitting $61.17. The stock had a trading volume of 1,637 shares, compared to its average volume of 398,644. The stock has a 50-day simple moving average of $58.18 and a two-hundred day simple moving average of $49.83. The stock has a market capitalization of $3.12 billion and a PE ratio of -39.80. Kymera Therapeutics has a 12 month low of $27.65 and a 12 month high of $91.92.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Friday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.30). Kymera Therapeutics had a negative net margin of 90.50% and a negative return on equity of 21.01%. The firm had revenue of $18.50 million during the quarter, compared to the consensus estimate of $18.81 million. The company’s revenue for the quarter was up 445.7% compared to the same quarter last year. Research analysts forecast that Kymera Therapeutics will post -1.54 earnings per share for the current year.

In related news, CFO Bruce N. Jacobs sold 10,000 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, September 3rd. The stock was sold at an average price of $60.12, for a total value of $601,200.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Richard Chesworth sold 54,000 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, August 17th. The shares were sold at an average price of $50.37, for a total value of $2,719,980.00. Following the completion of the sale, the insider now directly owns 54,000 shares in the company, valued at approximately $2,719,980. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 431,563 shares of company stock worth $25,136,186. 23.28% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the business. BlackRock Inc. increased its position in shares of Kymera Therapeutics by 6.9% during the 1st quarter. BlackRock Inc. now owns 1,513,923 shares of the company’s stock worth $58,831,000 after purchasing an additional 97,292 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Kymera Therapeutics during the 1st quarter worth approximately $4,847,000. Victory Capital Management Inc. acquired a new position in shares of Kymera Therapeutics during the 2nd quarter worth approximately $251,000. TD Asset Management Inc. increased its position in shares of Kymera Therapeutics by 15.6% during the 1st quarter. TD Asset Management Inc. now owns 26,599 shares of the company’s stock worth $1,034,000 after purchasing an additional 3,598 shares during the last quarter. Finally, Jennison Associates LLC increased its position in shares of Kymera Therapeutics by 169.2% during the 1st quarter. Jennison Associates LLC now owns 186,701 shares of the company’s stock worth $7,255,000 after purchasing an additional 117,346 shares during the last quarter. 51.99% of the stock is currently owned by hedge funds and other institutional investors.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases.

Featured Story: Dividend Aristocrat Index

Analyst Recommendations for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.